Paper
2020.12.07
Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, improves obesity via microbiota-driven mechanisms in mice
Publication
2020.09.15
Conference presentation regarding medicinal chemistry research on a GPR40 full agonist (SCO-267)
Publication
2020.09.10
Publication regarding medicinal chemistry research on a GPR40 full agonist (SCO-267)
Publication
2020.09.08
Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, may be a new therapeutic agent for diabetic kidney disease
Business
2020.08.11
SCOHIA initiates a phase 1 study on a dual GLP-1 and GIP receptor agonist (SCO-094)
Publication
2020.07.28
Publication regarding a preclinical study; SCO-267, a GPR40 full agonist, is a novel strategy to treat NAFLD
Business
2020.06.24
SCOHIA initiates a phase 2 proof of concept study on an enteropeptidase inhibitor (SCO-792) for diabetic kidney disease
Business
2020.05.28
Pipeline Information has been updated.
Business
2019.12.09
SCOHIA initiates a Phase1 study of a GPR40 full agonist (SCO-267)
Business
2019.11.28
SCOHIA initiates a phase 2 proof of concept study of an enteropeptidase inhibitor (SCO-792) in type 2 diabetes mellitus patients with obesity
Page Top